IGF-1 DES vs L-692,429
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and L-692,429 (L-692,429) — benefits, dosing, side effects, research data, and where to buy.
| Property | IGF-1 DES | L-692,429 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | L-692,429 |
| Molecular Weight | 7365 Da | N/A |
| Half-Life | ~20-30 minutes | unknown / study-dependent |
| Amino Acids | 67 | N/A |
| Typical Dose | — | 0.03-0.1 mg/kg |
| Route | — | Oral |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 30 |
| Research Status | Active Research | Pre-clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.